FDA NDA Move Puts Exelixis Colorectal Cancer Bet To The Test

Simply Wall St.

Feb 07

FDA accepts Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. The application is based on pivotal trial data for patients with advanced disease. This ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609512863"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609512863\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609512863?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119","is_english":true,"pubTime":"2026-02-07 02:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609512863","market":"sg","top_or_hot":-1,"title":"FDA NDA Move Puts Exelixis Colorectal Cancer Bet To The Test","media":"Simply Wall St.","content":"<div>\n<p>FDA accepts Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. The application is based on pivotal trial data for patients with advanced disease. This ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/fda-nda-move-puts-exelixis-colorectal-cancer-bet-to-the-test\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA NDA Move Puts Exelixis Colorectal Cancer Bet To The Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA NDA Move Puts Exelixis Colorectal Cancer Bet To The Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-07 02:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/fda-nda-move-puts-exelixis-colorectal-cancer-bet-to-the-test><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>FDA accepts Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. The application is based on pivotal trial data for patients with advanced disease. This ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/fda-nda-move-puts-exelixis-colorectal-cancer-bet-to-the-test\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/fda-nda-move-puts-exelixis-colorectal-cancer-bet-to-the-test","article_id":"2609512863","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/fda-nda-move-puts-exelixis-colorectal-cancer-bet-to-the-test","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609512863","pubTimestamp":1770401944,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"FDA accepts Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer.\nThe application is based on pivotal trial data for patients with advanced disease.\nThis step moves the investigational combination closer to potential commercial use in the United States.\n\nFor investors watching NasdaqGS:EXEL, this FDA filing milestone is an important datapoint in the company’s oncology pipeline. Exelixis focuses on cancer therapies, and colorectal cancer is a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4139":"生物科技","EXEL":"伊克力西斯"},"translate_title":"FDA NDA举措使Exelixis结直肠癌赌注受到考验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1.5},"content_text":"FDA accepts Exelixis' New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. The application is based on pivotal trial data for patients with advanced disease. This step moves the investigational combination closer to potential commercial use in the United States.  For investors watching NasdaqGS:EXEL, this FDA filing milestone is an important datapoint in the company’s oncology pipeline. Exelixis focuses on cancer therapies, and colorectal cancer is a large, high-need treatment area where additional options are often closely followed by clinicians and payers. This NDA acceptance does not guarantee approval. It does, however, start a formal regulatory review process that investors tend to track through upcoming FDA milestones. As timelines and any additional data updates emerge, they can affect how the market views Exelixis’ pipeline value and its potential role in metastatic colorectal cancer treatment. Stay updated on the most important news stories for Exelixis by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Exelixis. NasdaqGS:EXEL Earnings & Revenue Growth as at Feb 2026 How Exelixis stacks up against its biggest competitors The FDA’s acceptance of Exelixis’ NDA for the zanzalintinib plus atezolizumab combination in previously treated metastatic colorectal cancer moves this asset into a clearly defined review timetable, with a PDUFA action date set for December 3, 2026. For you as an investor, the key point is that this filing is based on a head to head phase 3 trial versus regorafenib in a difficult later line setting. This positions Exelixis directly against existing options from players like Bayer, while also extending its footprint alongside large immuno-oncology peers such as Merck and Bristol Myers Squibb. AdvertisementHow This Fits Into The Exelixis Narrative This news ties directly into the existing narratives that highlight Exelixis’ effort to reduce reliance on cabozantinib by building a broader oncology portfolio. Zanzalintinib, already being studied across several solid tumors, sits at the center of those views. An accepted NDA in colorectal cancer may be seen as one of the first real tests of whether that pipeline can support the kind of diversified, oncology-focused business profile many analysts have been discussing. Risks And Rewards Investors Should Weigh  🎁 A potential new colorectal cancer indication could open up an additional revenue stream in a large treatment setting if the combination secures approval and achieves meaningful adoption. 🎁 Positive overall survival data versus regorafenib in the intention to treat population gives Exelixis a concrete clinical result to point to as it talks to oncologists and payers. ⚠️ Overall survival data in patients without active liver metastases are still immature, so there is residual clinical and regulatory uncertainty until the planned final analysis in mid 2026. ⚠️ Concentration risk remains, because if future readouts or the FDA review do not align with expectations, sentiment around zanzalintinib could swing and affect how investors view the broader Exelixis story.  What To Watch Next From here, the milestones to keep on your radar are the final OS analysis in the non liver metastases subgroup, any safety or efficacy updates from regulators, and how oncologists react to the full STELLAR 303 data in practice as they compare it with other later line options. If you want to see how different investors are thinking about these moving parts, take some time to read the community views and analyst narratives for Exelixis in the company’s community narratives hub and decide which assumptions line up best with your own outlook.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Exelixis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}